The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

New England Journal of Medicine

Volumn 345, Issue 12, 2001, Pages 870-878

  Parving, Hans Henrik ^a   Lehnert, Hendrik ^b   Brochner Mortensen, Jens ^c   Gomis, Ramon ^d   Andersen, Steen ^a   Arner, Peter ^e  

^a STENO DIABETES CENTER   (Denmark)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF BARCELONA   (Spain)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; INSULIN; IRBESARTAN; ORAL ANTIDIABETIC AGENT; PLACEBO; STATINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; TREATMENT OUTCOME; URINARY EXCRETION;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0035922444     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011489     Document Type: Article

References (33)

1. Diabetic nephropathy
2. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
3. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus
4. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
5. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
6. Initiation and progression of diabetic nephropathy
7. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors?
8. Preanalytical and analytical factors involved in the determination of urinary immunoglobin G, albumin, alpha 1-microglobin and retinol binding protein using the Behring nephelometer system
9. The Jaffe reaction with creatinine: Reaction product and general reaction conditions
10. Monitoring kidney function in diabetic nephropathy
11. Glycated hemoglobin: Methodologies and clinical applications
12. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria
13. Nonparametric estimation from incomplete observations
14. Statistical aspects of the analysis of data from retrospective studies of disease
15. Regression models and life-tables
16. Captopril or conventional therapy in hypertensive type II diabetics: Three-year analysis
17. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria
18. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients
19. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine
20. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
21. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
22. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients
23. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
24. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
25. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
26. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment
27. Renoprotective therapy: Titration against urinary protein excretion
28. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?
29. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria
30. The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study
31. Prevention of diabetic renal disease with special reference to microalbuminuria
32. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy
33. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)